Andreza Ribeiro Simioni

Andreza Ribeiro Simioni

Auto-generated profile, based on publicly available information

Andreza Ribeiro Simioni

Universidade do Vale do Paraíba

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 August 2011 in Lasers in Medical Science
Verified
Journal Article
Closed access
PDF file
João Paulo Figueiró LongoJoão Paulo Figueiró Longo
João Paulo Figueiró Longo
SLSoraya Leal
Soraya Leal
ASAndreza R. Simioni
Andreza R. Simioni
MAMaria de Fátima Menezes Almeida-Santos
Maria de Fátima Menezes Almeida-Santos
ATAntonio Claudio Tedesco
Antonio Claudio Tedesco
RARicardo Azevedo
Ricardo Azevedo

15 January 2009 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
AAAndre Amaral
Andre Amaral
ABAnamelia Bocca
Anamelia Bocca
ARAlice M. Ribeiro
Alice M. Ribeiro
JNJanayna Nunes
Janayna Nunes
DPDanielle L. G. Peixoto
Danielle L. G. Peixoto
MFMaria Sueli S. Felipe
Maria Sueli S. Felipe
The present study reports on the preparation and testing of a desoxycholate amphotericin B (D-AMB) sustained delivery system based on poly(lactic-co-glycolic acid) (PLGA) and dimercaptosuccinic acid (DMSA) polymeric blends (Nano-D-AMB) aimed at reducing the number of AMB administrations required to treat mycosis. BALB/c mice were infected with the yeast Paracoccidioides brasiliensis intravenously to mimic the chronic form of paracoccidioidomycosis. At 30 days post-infection, the animals were treated with Nano-D-AMB [6 mg/kg of encapsulated D-AMB, intraperitoneally (ip), interval of 72 h] or D-AMB (2 mg/kg, ip, interval of 24 h). Drug efficacy was investigated by the fungal burden recovery from tissues. Toxicity was assessed by renal and hepatic biochemical parameters, physical appearance of the animals and haematological investigation. The control groups used were non-infected and the infected mice mock treated with PBS. Nano-D-AMB presented results comparable to free D-AMB, with a marked antifungal efficacy. The Nano-D-AMB-treated group presented lower loss of body weight and absence of stress sign (piloerection and hypotrichosis) observed after D-AMB treatment. No renal [blood urea nitrogen (BUN), creatinine] or hepatic (pyruvic and oxalacetic glutamic transaminases) biochemical abnormalities were found. The micronucleus assay showed no significant differences in both the micronucleus frequency and percentage of polychromatic erythrocytes for Nano-D-AMB, indicating the absence of genotoxicity and cytotoxic effects. The D-AMB-coated PLGA–DMSA nanoparticle showed antifungal efficacy, fewer undesirable effects and a favourable extended dosing interval. Nano-D-AMB comprises an AMB formulation able to lessen the number of drug administrations. Further studies would elucidate whether Nano-D-AMB would be useful to treat systemic fungal infections such as paracoccidioidomycosis, candidiasis, aspergillosis and cryptococcosis.

1 December 2010 in Journal of Photochemistry and Photobiology B: Biology
Verified
Journal Article
Closed access
SSSylvie Séguier
Sylvie Séguier
SSSergio L.S. Souza
Sergio L.S. Souza
ASAnna C.V. Sverzut
Anna C.V. Sverzut
ASAndreza R. Simioni
Andreza R. Simioni
Fernando Lucas PrimoFernando Lucas Primo
Fernando Lucas Primo
ATAntonio Claudio Tedesco
Antonio Claudio Tedesco

1 February 2009 in Journal of Photochemistry and Photobiology B: Biology
Verified
Journal Article
Closed access
João Paulo Figueiró LongoJoão Paulo Figueiró Longo
João Paulo Figueiró Longo
SLSilene Paulino Lozzi
Silene Paulino Lozzi
ASAndreza Ribeiro Simioni
Andreza Ribeiro Simioni
PMPaulo César Morais
Paulo César Morais
ATAntonio Claudio Tedesco
Antonio Claudio Tedesco
RARicardo Bentes Azevedo
Ricardo Bentes Azevedo

1 March 2009 in Journal of Liposome Research
Verified
Journal Article
Closed access
MNMariane Lira Nogueira
Mariane Lira Nogueira
MSMarigilson P. Siqueira-Moura
Marigilson P. Siqueira-Moura
HRHercília M. L. Rolim-Santos
Hercília M. L. Rolim-Santos
FGFábio C. S. Galetti
Fábio C. S. Galetti
ASAndreza R. Simioni
Andreza R. Simioni
NSNereide Stela Santos-Magalhães
Nereide Stela Santos-Magalhães
The cellular uptake and antimycobacterial activity of usnic acid (UA) and usnic acid-loaded liposomes (UA-LIPOs) were assessed on J774 macrophages. The minimal inhibitory concentration (MIC) and the minimal bactericidal concentration (MBC) of UA and UA-LIPO against Mycobacterium tuberculosis were determined. Concentrations required to inhibit 50% of cell proliferation (IC(50)) were 22.5 (+/-0.60) and 12.5 (+/-0.26) microg/ml, for UA and UA-LIPO, respectively. The MICs of UA and UA-LIPO were 6.5 and 5.8 microg/mL, respectively. The MBC of UA-LIPO was twice as low (16 microg/mL) as that of UA (32 microg/mL). An improvement in the intracellular uptake of UA-LIPO was found (21.6 x 10(4) +/- 28.3 x 10(2) c.p.s), in comparison with UA (9.5 x 10(4) +/- 11.4 x 10(2) c.p.s). In addition, UA-LIPO remains much longer inside macrophages (30 hours). All data obtained from the encapsulation of usnic acid into liposomes as a drug delivery system (DDS) indicate a strong interaction between UA-liposomes and J774 macrophages, thereby facilitating UA penetration into cells. Considering such a process as ruling the Mycobacterium-transfection by magrophages, we could state that associating UA with this DDS leads to an improvement in its antimycobacterial activity.

10 March 2010 in British Journal of Pharmacology
Verified
Journal Article
Closed access
PDF file
AAAndre Amaral
Andre Amaral
AMAlexandre F. Marques
Alexandre F. Marques
Julian E. MuñozJulian E. Muñoz
Julian E. Muñoz
ABAnamelia Bocca
Anamelia Bocca
ASAndreza R Simioni
Andreza R Simioni
MFMaria Sueli S Felipe
Maria Sueli S Felipe